There is a peculiar danger in public-health success: the better a system works, the easier it becomes to take it for granted. Bangladesh’s measles outbreak is demonstrating that paradox brutally.
By July 11, 2026, Bangladesh reportedly recorded more than 1,07,000 suspected cases, nearly 13,000 laboratory-confirmed infections and over 753 confirmed or suspected measles-related deaths since mid-March. Cases and deaths are still being reported. The numbers are shocking; their history is more instructive.
Bangladesh has long been an immunisation success, achieving high coverage earlier than many comparable countries. International agencies, including the World Health Organization (WHO), have repeatedly praised its gains. This is not the story of a system that never worked, but of one that worked impressively, then allowed weaknesses to accumulate beneath reassuring averages.
That is why the outbreak matters even far beyond Bangladesh. Measles is an unforgiving auditor of health systems. As one of the most contagious human infections, it generally requires 95 percent population immunity, maintained through two doses of the measles vaccine. Protection must also be geographically even. A country can report respectable national coverage while neighbourhoods, migrant populations, or informal settlements remain exposed.
In 2025, Unicef estimated that around 70,000 Bangladeshi children had received no routine vaccines and another 4,00,000 were under-immunised. Full immunisation coverage was lower in urban areas than in rural ones. By April 2026, WHO reported measles in 58 of 64 districts. Of reported cases, 79 percent were in children under five; two-thirds were under two; one-third were infants too young for the routine first dose.
Furthermore, recent reporting by Bangla daily Prothom Alo uncovered a major gap between the number of children reached by the Vitamin A initiative and those targeted for the emergency measles campaign, a discrepancy that effectively left millions of children without protection against the deadly virus.
These figures describe the epidemiology of inequality. Children do not automatically miss jabs. They are missed when immunisation clinic hours clash with work, families move, records fragment, staff are overstretched, vaccines are unavailable, or services are weakest where populations are densest.
Programme failures deepen the vulnerability. WHO has linked declining protection and the current outbreak to the gaps in routine immunisation, absence of regular nationwide supplementary measles-rubella campaigns after 2020, and vaccine stockouts in 2024 and 2025. Coverage estimates also showed deterioration in measles second-dose protection. Administrative responsibility may be disputed, but epidemiology is always less diplomatic. When susceptible children accumulate, measles eventually finds them.
The high mortality in the current outbreak demands equal attention. WHO’s early assessment reported a case-fatality ratio of about 0.9 percent among suspected cases. Mortality is shaped not only by vaccination status but by malnutrition, vitamin A deficiency, delayed care, pneumonia, diarrhoea and overstretched hospitals.
There is no doubt that the emergency response to the outbreak has been effective. From April 5, the campaign expanded from high-risk areas nationwide, lowered eligibility to six months, and used fixed sites, outreach, mobile teams and extended hours. By late May, more than 1.84 crore children had reportedly been vaccinated with the measles vaccine, exceeding the target. Yet the measles-related deaths continued. Vaccines cannot reverse infections already incubating, and one campaign cannot instantly eliminate the accumulated susceptibility.
The deeper policy challenge is familiar. Governments often find money, personnel and political attention after a crisis more easily than they fund quiet machinery that prevents one.
When it comes to measles outbreaks, Bangladesh is not an aberration. The Americas, the first WHO region to eliminate measles, lost that distinction in November 2025 after sustained transmission re-emerged in Canada. By early November, the Pan American Health Organization (PAHO) had recorded 12,596 confirmed cases across ten countries, 30 times the 2024 figure, with 95 percent concentrated in Canada, Mexico and the United States. By July 2, 2026, the US had recorded 2,170 confirmed cases, almost matching its 2025 total. After the pandemic, several countries across different parts of the world had witnessed a sharp rise in measles cases
The outbreak in Bangladesh has lessons for many low- and middle-income countries that are aiming for measles elimination. It is simple: measles returns when immunity becomes patchy, whether the gap is caused by weak primary care, disrupted supply chains, conflict, urban exclusion, misinformation, or complacency.
South-East Asia has made elimination a regional goal. WHO member states extended the target for measles and rubella elimination to 2026, backed by a 2024-28 strategy centred on 95 percent two-dose coverage, surveillance and outbreak response. Bangladesh had committed to elimination years earlier. The outbreak is therefore not merely a setback; it warns that campaigns cannot deliver elimination while routine systems remain porous.
What should change? The lessons are global. First, governments must stop governing immunisation by national averages. Ministries need near-real-time dashboards in districts, municipalities and neighbourhoods showing first-dose coverage, second-dose dropout, missed settlements, stock availability and clusters of susceptibility. National success should be judged by the worst-performing pockets, not only the mean.
Second, in immunisation programmes, the zero-dose children should become an operational priority. Finding them requires micro-planning, household mapping, mobile teams, evening and weekend sessions, vaccination at schools and nurseries, integration with nutrition and primary care services, and interoperable records that follow mobile families.
Third, immunisation programmes need procurement resilience. Countries should maintain transparent stock monitoring, buffer supplies, multiple procurement safeguards and accountability for shortages.
Fourth, outbreak control must combine transmission control with mortality reduction. Vaccination campaigns should be linked with vitamin A administration where indicated, nutrition screening, early referral, oxygen capacity, paediatric triage and treatment of complications.
Finally, donors and governments should reward maintenance. Cold chains, vaccinators, supervisors, laboratory networks, surveillance officers and local outreach are invisible when they succeed. That invisibility is not evidence that they are dispensable. It is evidence that prevention is working. Bangladesh’s outbreak should not erase its earlier achievements. It should force a more demanding definition of success.
The children getting infected with measles is not evidence that vaccines failed. They are evidence that protection became uneven, surveillance too slow, and routine systems lost reach. Every country with a reassuring coverage figure should study that distinction. Measles has a ruthless way of finding the children hidden inside an average and of exposing the complacency hidden inside success. Vaccination programmes are a flagship success of public health interventions. It is our moral responsibility to protect every child who can be protected.
Dr Chandrakant Lahariya, an internationally recognised public health expert, with nearly 18 years of experience at WHO, Unicef and other UN agencies, writes from New Delhi, India.
Views expressed in this article are the author's own.
Follow The Daily Star Opinion on Facebook for the latest opinions, commentaries, and analyses by experts and professionals. To contribute your article or letter to The Daily Star Opinion, see our guidelines for submission.
